On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...

Ph.D., President and Chief Executive Officer of Aileron. "Additionally, we saw dose dependent effects in five biomarkers ...

Waltham, Massachusetts Friday, November 15, 2024, 15:00 Hrs [IST] ...

Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Aileron Therapeutics (ALRN) announced positive topline data from Cohort 2 of its Phase 1b clinical trial evaluating the safety and tolerability ...

Short interest in Aileron Therapeutics Inc (NASDAQ:ALRN) decreased during the last reporting period, falling from 297.75K to 255.55K. This put 1.18% of the company's publicly available shares short.

Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights ...

Jet.AI Inc. (NASDAQ: JTAI) shares are trading higher Wednesday after the company's board approved a $2 million share ...

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) in a report released on Monday. The brokerage set a “hold” rating on the stock.

Atossa Therapeutics focuses on developing endoxifen for hormone receptor-positive breast cancer, with promising early-stage trial results but lacks definitive proof of efficacy. The company has ...